The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors-Reference-Cited by-同舟云学术

The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors

Published:2013-06 Issue:6 Volume:24 Page:1653-1659
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Yamamoto N.,Murakami H.,Nishina T.,Hirashima T.,Sugio K.,Muro K.,Takahashi T.,Naito T.,Yasui H.,Akinaga S.,Koh Y.,Boku N.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/6/1653/13789026/mdt014.pdf

Reference27 articles.

1. Drug development of MET inhibitors: Targeting oncogene addiction and expedience;Comoglio;Nat Rev Drug Discov,2008

2. Targeting the HGF/c-Met axis: state of play;Yap;Mol Cancer Ther,2010

3. Targeting the HGF/Met signalling pathway in cancer;Cecchi;Eur J Cancer,2010

4. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer;Eder;Clin Cancer Res,2009

5. The role of the c-Met pathway in lung cancer and the potential for targeted therapy;Sattler;Ther Adv Med Oncol,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics;Cancers;2023-06-18

2. Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo;Clinical Pharmacology & Therapeutics;2022-04-17

3. Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted;Cancers;2022-02-23

4. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors;Investigational New Drugs;2021-06-28

5. A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma;Cancer Science;2020-08-26